Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference16 articles.
1. Plosker GL (2015) Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 75(3):297–308
2. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807
3. Harrison CN, Vannucchi AM, Kiladjian JJ et al (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 30(8):1701–1707
4. Blechman AB, Cabell CE, Weinberger CH, Duckworth A, Leitenberger JJ, Zwald FO, Russell MA (2017) Aggressive skin cancers occurring in patients treated with the Janus kinase inhibitor ruxolitinib. J Drugs Dermatol 16(5):508–511
5. Fabiano A, Calzavara-Pinton P, Monari P, Moggio E, Pellacani G, Manganoni AM, Gualdi G (2015) Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with ruxolitinib. Br J Dermatol 173(4):1098–1099
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献